U.S. FDA Approves ALK’s Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis

U.S. FDA Approves ALK’s Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis

ROUND ROCK, Texas, April 19, 2021 /PRNewswire/ — ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF), ...
read more
FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up

FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up

The US Food and Drug Administration (FDA) has appr...
read more
FDA: COVID-19 Not Transmitted by Food or Packaging

FDA: COVID-19 Not Transmitted by Food or Packaging

There is no evidence you can catch coronavirus thr...
read more
FDA issues alert on hand sanitizer products from Mexico

FDA issues alert on hand sanitizer products from Mexico

Fox News Flash top headlines for January 27 Fox Ne...
read more
FDA Approves Lupkynis

FDA Approves Lupkynis

FDA Approves Lupkynis (voclosporin) for Adult Pati...
read more
FDA Advisory Committee OKs Pfizer-BioNTech COVID-19 Vaccine

FDA Advisory Committee OKs Pfizer-BioNTech COVID-19 Vaccine

THURSDAY, Dec. 10, 2020 — The U.S. Food and ...
read more
Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy

Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy

ATLANTA, Nov. 17, 2020 /PRNewswire/ — UCB, a...
read more
Third COVID Vaccine Shows Effectiveness; FDA Approves New Treatment

Third COVID Vaccine Shows Effectiveness; FDA Approves New Treatment

MONDAY, Nov. 23, 2020 – Americans were greeted w...
read more
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE N...
read more
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926

Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926

NEW YORK–(BUSINESS WIRE)–October 01, 2...
read more
1 2 3